


CONTRACT



CONservative TReatment of Appendicitis in Children – a randomised controlled Trial – CONTRACT (Feasibility study)

University Hospital Southampton **NHS**
NHS Foundation Trust

Version 3, 04-July-2017

UNIVERSITY OF
Southampton

SPONSOR: University Hospital Southampton NHS Foundation Trust
COORDINATING CENTRE: Southampton Clinical Trials Unit

ISRCTN reference:	ISRCTN15830435
Ethics reference number:	16/SC/0596
Sponsor reference number:	RMH CHI 0624
Funder reference number:	14/192/90
ICD10	K35



Protocol authorised by:

Name: Nigel Hall **Role:** Chief Investigator

Signature:  **Date:** 10/7/2017

Name: Gareth Griffiths **Role:** Director of SCTU

Signature:  **Date:** 6/7/2017

Mikayala King
Research Governance & QA
Manager

Name: University Hospital Southampton NHS Foundation Trust **Role:** On behalf of Sponsor

Signature:  **Date:** 12 JUL 2017

MAIN STUDY CONTACT

Chief Investigator and Medical Expert: Mr Nigel Hall
University Surgery Unit, MP 816
Southampton General Hospital,
Southampton SO16 6YD
Tel: 07976153315
Email: n.j.hall@soton.ac.uk

STUDY COORDINATION CENTRE

For general study and clinical queries e.g. participant queries, study supplies, data collection, please contact in the first instance:

CONTRACT Clinical Trial Manager(s) Tel: 023 8120 4128
Email: CONTRACT@soton.ac.uk
Address: Southampton Clinical Trials Unit Tel: 023 8120 5154
Southampton General Hospital Fax: 0844 774 0621
Tremona Road Email: ctu@soton.ac.uk
SOUTHAMPTON, SO16 6YD Web: www.southampton.ac.uk/ctu

SPONSOR

University Hospital Southampton NHS Foundation Trust is the research sponsor for this study. For further information regarding sponsorship conditions, please contact the Director of Research and Development at:

Address: R&D Department Tel: 023 8120 4989
University Hospital Southampton NHS Foundation Trust Fax: 023 8120 8678
SGH, Level E, Laboratory & Pathology Block, SCBR, MP 138 Web: www.uhs.nhs.uk
Tremona Road
SOUTHAMPTON
SO16 6YD

CO-INVESTIGATOR(S)

Co-Investigators can be contacted via the Trial Coordination Centre.

Mr Dean Rex		St George's Healthcare NHS Trust
Ms Harriet Corbett		Alder Hey Children's NHS Foundation Trust
Mr Michael Stanton		University Hospital Southampton NHS Foundation Trust
Dr Isabel Reading	Statistician	University of Southampton
Dr Wendy Wood		University of Southampton
Ms Maria Chorooglou	Health Economist	University of Southampton
Prof Bridget Young		University of Liverpool
Dr Erin Walker		Great Ormond Street Hospital for Children NHS Trust
Dr William Van't Hoff		Great Ormond Street Hospital for Children NHS Trust
Prof Jane Blazeby		University of Bristol
Dr Esther Crawley		University of Bristol
Dr Simon Eaton		UCL Institute of Child Health
Simon Grist	PPI	Southampton

FUNDER

This study is primarily funded by NIHR Health Technology Assessment (14/192/90) with additional support from Southampton Clinical Trials Unit.

Protocol Information

This protocol describes the CONTRACT study and provides information about procedures for entering participants. The protocol should not be used as a guide for the treatment of other non-study participants; every care was taken in its drafting, but corrections or amendments may be necessary. These will be circulated to investigators in the study, but sites entering participants for the first time are advised to contact Southampton Clinical Trials Unit to confirm they have the most recent version.

Compliance

This study will adhere to the principles of Good Clinical Practice (GCP). It will be conducted in compliance with the protocol, the Data Protection Act and all other regulatory requirements, as appropriate.

TABLE OF CONTENTS

OVERALL STUDY SCHEDULE	9
<i>SCHEDULE OF OBSERVATIONS AND PROCEDURES FOR CLINICAL TRIAL</i>	10
1 INTRODUCTION	11
1.1 BACKGROUND	11
1.2 RATIONALE AND RISK BENEFITS FOR CURRENT STUDY	12
2 STUDY OBJECTIVES	12
3 STUDY DESIGN	13
3.1 DEFINITION OF END OF STUDY	14
4 SELECTION AND ENROLMENT OF PARTICIPANTS	14
4.1 CONSENT	14
4.2 INCLUSION CRITERIA	15
4.3 EXCLUSION CRITERIA	15
4.4 SCREENING FAILURES	15
4.5 REGISTRATION/RANDOMISATION PROCEDURES	15
5 STUDY OBSERVATIONS AND PROCEDURES	16
5.1 SCREENING PROCEDURES	16
5.2 STUDY PROCEDURES	16
5.3 FOLLOW UP	22
5.4 DEVIATIONS AND SERIOUS BREACHES	22
5.5 STUDY DISCONTINUATION	22
5.6 WITHDRAWAL	23
5.7 PROHIBITED AND RESTRICTED THERAPIES DURING THE STUDY	23
5.8 BLINDING AND PROCEDURES FOR EMERGENCY UNBLINDING	23
6 SAFETY	23
6.1 DEFINITIONS	23
6.2 SERIOUSNESS	24
6.3 CAUSALITY	24
6.4 EXPECTEDNESS	25
6.5 REPORTING PROCEDURES	26
6.6 SCTU RESPONSIBILITIES FOR SAFETY REPORTING TO REC	27
7 STATISTICS AND DATA ANALYSES	27
7.1 METHOD OF RANDOMISATION	27
7.2 SAMPLE SIZE	27
7.3 INTERIM ANALYSIS	28
7.4 STATISTICAL ANALYSIS PLAN (SAP)	28
8 REGULATORY	30
8.1 CLINICAL TRIAL AUTHORISATION	30
9 ETHICAL CONSIDERATIONS	30

9.1	SPECIFIC ETHICAL CONSIDERATIONS	30
9.2	ETHICAL APPROVAL	31
9.3	INFORMED CONSENT PROCESS	31
9.4	CONFIDENTIALITY	31
10	SPONSOR	31
10.1	INDEMNITY	31
10.2	FUNDING	32
10.3	AUDITS AND INSPECTIONS	32
11	STUDY OVERSIGHT GROUPS	32
11.1	STUDY MANAGEMENT GROUP (SMG)	32
11.2	TRIAL STEERING COMMITTEE (TSC)	32
11.3	DATA MONITORING AND SAFETY COMMITTEE (DMSC)	33
12	DATA MANAGEMENT	33
13	MONITORING	34
13.1	CENTRAL MONITORING	34
13.2	CLINICAL SITE MONITORING	34
13.3	SOURCE DATA	34
14	RECORD RETENTION AND ARCHIVING	35
15	PUBLICATION POLICY	35
16	REFERENCES	35
17	APPENDICES	40

LIST OF ABBREVIATIONS

AE	Adverse Event
A&E	Accident and Emergency department
CHU-9D	Child Health Utility 9D
COS	Core Outcome Set
eCRF	Electronic Case Report Form
CRF	Clinical Research Facility
CRP	C Reactive Protein
CRN	Clinical Research Network
CSRI	Client Service Receipt Inventory
CTCAE	Common Terminology Criteria for Adverse Events
DMSC	Data Monitoring and Safety Committee
GCP	Good Clinical Practice
HE	Health Economics
ISF	Investigator Site File
IV	Intravenous
MHRA	Medicines and Healthcare products Regulatory Agency
NBM	Nil by mouth
NIHR	National Institute of Health Research
PICU	Paediatric Intensive Care Unit
PPI	Patient and Public Involvement
RCT	Randomised Clinical Trial
REC	Research Ethics Committee
RN	Research Nurse
SAE	Serious Adverse Event
SCTU	Southampton Clinical Trials Unit
SMG	Study Management Group
SSAG	Study Specific Advisory Group
TMF	Trial Master File
TSC	Trial Steering Committee
WBC	White Blood Count
YPAG	Young Persons Advisory Group

KEYWORDS

appendicitis; appendicectomy; abdominal pain; core outcome set; patient and public involvement; randomised controlled trial; evidence based medicine; qualitative research

STUDY SYNOPSIS


Short title/Acronym:	CONTRACT
Full title:	CONservative Treatment of Appendicitis in Children – a randomised controlled Trial (Feasibility)

Study Phase:	Feasibility
Population:	Children (aged 4-15 years) with a clinical diagnosis of acute uncomplicated appendicitis
Primary Objective:	Assess whether it is feasible to conduct a multi-centre randomised controlled trial testing the effectiveness and cost-effectiveness of a non-operative treatment pathway for the treatment of acute uncomplicated appendicitis in children
Secondary Objective:	<ul style="list-style-type: none"> • Assess the willingness of parents and children to be enrolled in, and surgeons to recruit to a randomised study comparing operative versus non-operative treatment and identify anticipated recruitment rate • Identify strategies to optimise surgeon-family communication to inform the future RCT • Enhance the design of a future RCT from the perspectives of stakeholders at participating sites (children, parents, surgeons and nurses) • Identify what core outcomes family members and surgeons regard as important to measure in a future RCT and to develop a core outcome set • Assess the equipoise and willingness of UK paediatric surgeons to participate in a future RCT • Generate data to allow for the design of a definitive RCT, including sample size calculation and identification of key cost drivers and other parameters necessary to perform a full economic analysis • Examine clinical outcomes of children with acute appendicitis treated without an operation including an initial assessment of efficacy and safety of this treatment pathway in our centres • Ensure the whole of the research programme is well informed by a group of children and parents, our SSAG
Rationale:	Currently, there is no good evidence to inform surgeons, patients and parents whether non-operative treatment of acute uncomplicated appendicitis in children is effective and cost effective.
Study Design:	Mixed methods feasibility study comprising: <ul style="list-style-type: none"> • Randomised controlled trial • Embedded and parallel qualitative and survey study • Development of core outcome set
Sample size :	No target as feasibility of recruitment being tested – patients will be recruited over 12 months (approx. 65 pts)
Treatment/Intervention:	A. Non-operative treatment pathway (broad-spectrum antibiotics and active observation) B. Appendicectomy

URL for Database:	https://login.imedidata.com/login
--------------------------	---

URL for randomisation:	www.formsvision.com
Primary Study Endpoints:	Proportion of eligible patients recruited to the study over 12 months
Secondary Study Endpoints:	Audio-recordings of recruitment consultations and qualitative interviews Core Outcome Set Survey work Clinical outcomes of clinical trial Review of SSAG activity
Total Number of Sites:	3 paediatric surgical teaching hospitals

STUDY SCHEMA



NBM = nil by mouth

† non-operative treatment = NBM/sips for initial 12h minimum then advance diet as tolerates; iv antibiotics 24h minimum, change to oral once afebrile for 24h, total course 10 days; analgesia


* appendicectomy group – no routine use of nasogastric tube or urinary catheter, advance diet as tolerates

\$ defined as either seeing a hole in the appendix or faecal matter/faecolith in the peritoneal cavity

\$\$ continue iv antibiotics until afebrile for 24h, then change to oral; minimum 5 days total antibiotics

** criteria for discharge include: vital signs within normal limits, tolerating light diet, adequate oral analgesia, mobile

OVERALL STUDY SCHEDULE



RN – research nurses; HE – health economic; CRF – clinical research facility

SCHEDULE OF OBSERVATIONS AND PROCEDURES FOR CLINICAL TRIAL

Visit / Time point:	Baseline	Randomisation to 24 hours	24 hrs to 48 hrs	48 hrs to Discharge	Discharge to 2 weeks	Visit 1 6 weeks	Visit 2 3 months	Visit 3 6 months
Screening log	X							
Informed Consent	X							
Eligibility evaluation	X	X	X	X	X	X	X	
Medical History	X	X	X	X	X	X	X	X
Diagnostic Tests (blood test – Total WBC /CRP /Neutrophil, CT scan, Ultrasound)	X							
Pregnancy Test	X							
Physical Exam (Abdomen exam)	X					X		
Vital Signs (Temperature)	X							
Appendicectomy (where appropriate)		X						
Clinician Assessment		X	X					
Antibiotic log		X	X	X	X	X	X	X
Discharge Assessment				X				
Concurrent Medication (Pain relief only)		X	X	X	X	X	X	X
Adverse Events		X	X	X	X	X	X	X
Health Economics – resource use	X	X	X	X	X	X	X	X
EQ5D / CHU-9D	X			X	X	X	X	X
Patient Diary Card					X			
Client Service Receipt Inventory (CSRI)						X		X
Qualitative Interviews						X		

NB: The Participant/legal representative is free to withdraw consent at any time without providing a reason. When withdrawn, the participant will continue to receive standard clinical care. Follow up data will continue to be collected (unless the participant/legal representative has specifically stated that they do not want this to happen).

1 INTRODUCTION

1.1 BACKGROUND

Acute appendicitis is the commonest surgical emergency in children [12]. The lifetime risk of developing appendicitis is 7-8% and the commonest age for developing appendicitis is in the early teens. Appendicectomy is considered the gold standard treatment for acute appendicitis by most surgeons. As a result in the year 2012-13 (most recent period with available data) there were 9,035 emergency appendicectomies in England in children.

Many parents find the proposal that their child needs emergency surgery frightening and one they are keen to avoid if an alternative is available. Our PPI work confirms this. Families frequently ask *“Does my child really need an operation?”*

Although appendicectomy is usually a simple procedure, it requires a general anaesthetic and an abdominal operation with inherent risks. Complication rate of appendicectomy (including wound infection, intra-abdominal abscess, and adhesional small bowel obstruction) is up to 25% [13] with a need for hospital readmission in 4-5% [14, 15]. A contemporary estimation of these risks is available from the National Appendicectomy Audit, a nationwide audit of outcomes of appendicectomy for acute appendicitis in 19 Specialist Paediatric Surgery Centres in the UK co-ordinated by the Chief Investigator [9]. Over a 2 month period, 242 appendicectomies for acute appendicitis were performed. The negative (histologically normal) appendicectomy rate was 10.3% and the 30-day adverse event rate (a composite of readmission, re-intervention, pelvic collection and wound infection) was 15.3%.

The financial burden of paediatric appendicitis in England is in excess of £21 million per year. Appendicectomy requires significant resource use including need for out-of-hours surgery (45% of all paediatric appendicectomies were performed between 1800 and 0800 in the recent audit).

An alternative approach to the treatment of children with acute appendicitis would be treatment with antibiotics and without an appendicectomy. Whilst there is growing scientific interest in the use of non-operative treatment with antibiotics, we do not yet know whether this approach is safe and effective. However, there are several potential benefits to a non-operative approach over surgery including:

- avoiding the trauma, physiological stress, psychological distress and physical scarring of an operation
- avoiding complications as a result of surgery or general anaesthesia
- reduced NHS resource use with potential for significant savings if non-operative treatment is effective (over £500 per case based on HRG tariff).

However, such an approach would only be acceptable if antibiotic treatment is safe, successful in the majority of cases and the risk of recurrent appendicitis is low.

It has been known for some time that acute appendicitis can be treated successfully by antibiotics alone, in the context of remote environments without surgical service capability [16]. However, the role of non-operative treatment as primary therapy has only recently come under consideration in developed healthcare systems initially in adults [13, 17-23] and more recently in children [1, 4, 5].

Although studies in adults may be extrapolated to children, to do so is problematic since there are key differences in appendicitis occurring in adults compared to children. A paediatric RCT is necessary since appendicitis presents differently in children and adults, the intra-abdominal inflammatory response is different in adults and children [33, 34] and may be more amenable to antibiotic treatment alone, and the psychosocial and economic impact of appendicitis in children affects the whole family, rather than just the individual.

There is just one RCT, recently performed in Sweden, in which the Chief Investigator and one co-investigator (SE) were involved in the design, running and analysis, comparing non-operative

treatment with antibiotics with appendicectomy in children with acute appendicitis [5]. Fifty children (aged 5-15 years) with acute non-perforated appendicitis were randomised to antibiotics (n=24) or appendicectomy (n=26). All children in the surgery group had histopathologically-confirmed acute appendicitis and none experienced a significant surgical complication. In the antibiotic group, 2 of 24 underwent appendicectomy within the time of primary antibiotic treatment, and 1 further child required appendicectomy for histologically-proven, recurrent acute appendicitis 9 months later. Of eligible participants, the recruitment rate was 40%, the drop-out rate following treatment allocation was 2% (1 patient) and no patient was lost to follow-up by 1 year. This pilot study was not powered to compare the efficacy of antibiotics vs surgery, but was conducted to inform the design of a large multicentre RCT including North America which is still in planning stage.

Safety of non-operative treatment: importantly none of the existing studies of non-operative treatment of acute uncomplicated appendicitis in children have identified any safety concerns regarding the intervention [1-6].

Recurrent appendicitis is a consideration in children who receive non-operative treatment that is not applicable to children treated with appendicectomy. In adults [17-20, 25] the incidence of recurrence (within 1 year) is around 15%. The incidence of recurrence in children is largely unknown although the recent pilot study of non-operative treatment of appendicitis in children with 1 year follow-up reported a recurrence rate of 5% [5]. A systematic review of recurrent appendicitis following successful non-operative treatment of an appendix mass (a distinct clinical entity from acute appendicitis) in children estimated an incidence of 20% [35]. These data are the closest we have to an estimate in children.

1.2 RATIONALE AND RISK BENEFITS FOR CURRENT STUDY

Currently, there is no good evidence to inform surgeons, patients and parents whether non-operative treatment of acute uncomplicated appendicitis in children is effective and cost effective. To determine this we intend to perform a multicentre prospective randomised controlled trial. Prior to such a trial, a feasibility study is necessary to determine whether recruitment to a large RCT is feasible, to refine methodology and outcomes, and engage with stakeholders.

We have also embedded qualitative methods within this trial to optimise recruitment and enhance trial design and our treatment approach [38, 39]. We refer to this qualitative study as the 'Communication Sub-study' in the Information Sheets and Consent Forms to assist patient and family understanding.

As no COS of relevance to trials involving non-operative treatment of children with acute appendicitis currently exists [53], we will define a COS, involving multiple stakeholders (surgeons, children and parents) in the process. This will ensure that the outcomes we measure in our planned RCT will have the most significant impact and are relevant not only to surgeons but also to children and their families.

2 STUDY OBJECTIVES

In the long term, we aim to determine if it is effective and cost-effective to treat children with acute uncomplicated appendicitis with a non-operative treatment pathway instead of appendicectomy. This will require a large, multicentre non-inferiority RCT.

First we will perform this feasibility study, the aim of which is to answer the research question:

Is it feasible and acceptable to conduct a multi-centre randomised controlled trial testing the effectiveness and cost-effectiveness of a non-operative treatment pathway for the treatment of acute uncomplicated appendicitis in children?

Objective		Endpoint used to evaluate
Primary:	Assess whether it is feasible to conduct a multi-centre randomised controlled trial testing the effectiveness and cost-effectiveness of a non-operative treatment pathway for the treatment of acute uncomplicated appendicitis in children	Proportion of eligible patients recruited to the study over 12 months
Secondary:	Assess the willingness of parents and children to be enrolled in, and surgeons to recruit to, a randomised study comparing operative versus non-operative treatment and identify anticipated recruitment rate	Embedded qualitative study
	Identify strategies to optimise surgeon-family communication to inform the future RCT	Embedded qualitative study
	Enhance the design of a future RCT from the perspectives of stakeholders at participating sites (children, parents, surgeons and nurses)	Embedded qualitative study
	Identify what core outcomes family members and surgeons regard as important to measure in a future RCT and to develop a core outcome set	Core Outcome Set
	Assess the equipoise and willingness of UK paediatric surgeons to participate in a future RCT	Survey work
	Generate data to allow for the design of a definitive RCT, including sample size calculation and identification of key cost drivers and other parameters necessary to perform a full economic analysis	Clinical outcomes of clinical trial including response rate to initial treatment pathway, complications and rate of recurrent appendicitis
	Examine clinical outcomes of children with acute appendicitis treated without an operation including an initial assessment of efficacy and safety of this treatment pathway in our centres	Clinical outcomes of clinical trial (as above)
	Ensure the whole of the research programme is well informed by a group of children and parents, our SSAG	Review of Study Specific Advisory Group (SSAG) activity

3 STUDY DESIGN

The proposed work comprises a number of inter-related elements:

- A. A randomised controlled feasibility trial of children comparing a non-operative treatment pathway with appendicectomy. Both groups of children will receive broad spectrum antibiotics from the point of enrolment; one group of children will undergo urgent appendicectomy, the other will be treated non-operatively with continuation of broad spectrum intravenous antibiotics. A standardised treatment pathway (See Trial Schema) will be used for patients in both arms of the study. All patients will be followed-up with visits at 6 weeks, 3 months and 6 months.
- B. A detailed program of qualitative and quantitative research embedded within the above feasibility trial which will be used to optimise the design and conduct of a future RCT of non-operative treatment versus appendicectomy in the treatment of acute uncomplicated appendicitis in children.
- C. The development of a COS for the non-operative treatment of children with uncomplicated acute appendicitis for use in our future trial and by the wider research community (see appendix A).

3.1 DEFINITION OF END OF STUDY

The study will end once the final participant recruited has completed the 6 month follow up period.

4 SELECTION AND ENROLMENT OF PARTICIPANTS

4.1 CONSENT

Eligible participants will be identified by the clinical team at time of diagnosis of acute appendicitis.

Recruitment will be performed by surgeons and supported by research nurses since our preparatory work, with the NIHR CRN (Children) young person's advisory groups (YPAGs), has indicated that parents do not feel it appropriate to be recruited into this trial by anyone other than a surgeon. The CRN has also indicated that they do not think it is appropriate for nurses to recruit to this study alone due to the nature of the intervention which will challenge commonly-held beliefs about appendicectomy as best treatment for appendicitis, and the relatively short timeframe necessary for a decision to be made. We will utilise members of the clinical team (Specialist Surgical Trainees and Consultants) to recruit patients to the study in conjunction with research nurses. Recruitment capacity will therefore be available 16 hrs per day. This provides a realistic approach for a future multicentre trial.

Parents will be approached by a member of the surgical team and a research nurse who will explain the study to them and invite them to participate. Prior to this discussion verbal permission will be taken for the recruitment discussion to be voice recorded. The CONTRACT study will be explained to parents and children with the aid of age specific information sheets and a short video presentation. The patient video will also be made available via a web link to allow parents or guardians, who cannot be in hospital with their children at the time of recruitment, to access the same trial information as the consenting parent or guardian.

Written consent for inclusion in the clinical trial will be obtained from all families including assent (as opposed to consent) from children age 12 years or older who wish to give it (as suggested by our pre-study PPI work with young people). Consent for CONTRACT will be sought only after a full explanation of the study has been given and an information leaflet offered. At this time, written consent will also be sought for keeping and including the voice recording of the recruitment conversation in the qualitative analysis for the Communication Sub-study. If consent to keep the recording is not provided then the recording will be deleted.

We are sensitive to the need for participants and families to be given adequate time to consider the study yet there is also a need for a decision to be made within a short period of time. Whilst appendicectomy is not typically a true surgical emergency it is considered an urgent procedure. The consent process is therefore 'time-constrained' rather than truly urgent. Participants will be made aware of this and consent will be obtained within a maximum of 4 hours of first discussion of the study. The research process will never impede on provision of safe and effective patient care.

We will provide an educational package to clinical staff at each centre. This will include educational evenings at or near each centre to which all members of the clinical team (core and specialist surgical trainees, research nurses and consultant surgeons); a short video to

be shown to potential participants during the recruitment process; age appropriate PIS and consent form.

The right of the participant to refuse to participate without giving reasons will be respected. After the participant has entered the study the clinician remains free to give alternative treatment to that specified in the protocol at any stage if he/she feels it is in the participant's best interest, but the reasons for doing so should be recorded. In these cases the participant remains within the study for the purposes of follow-up and data analysis. All participants are free to withdraw at any time from the protocol treatment without giving reasons and without prejudicing further treatment.

Upon completion of the informed consent form, a copy will be given to the patient/parents, a copy stored in the patient's medical notes, a copy sent to the SCTU and the original filed in the site trial file. The SCTU copy should be emailed to uhs.sctu@nhs.net using a secure nhs.net email address to allow for central monitoring.

4.2 INCLUSION CRITERIA

- Child age 4 – 15 years (<16 years and >3 years)
- Clinical diagnosis, either with or without radiological assessment, of acute appendicitis which prior to study commencement would be treated with appendicectomy
- Written informed parental consent, with child assent if appropriate

4.3 EXCLUSION CRITERIA

- Clinical signs or radiological findings to suggest perforated appendicitis
- Presentation with appendix mass
- Previous episode of appendicitis or appendix mass treated non-operatively
- Major anaesthetic risk precluding allocation to the appendicectomy arm
- Known antibiotic allergy preventing allocation to non-operative treatment arm
- Antibiotic treatment started at referring institution (defined as 2 or more doses administered)
- Cystic fibrosis (there is a higher background incidence of appendicitis in this population and they are at an increased risk of recurrence. Therefore, there is a lack of equipoise between treatment arms for this group of children)
- Positive pregnancy test
- Current treatment for malignancy

4.4 SCREENING FAILURES

The Research Nurse in each Centre will complete a screening log detailing each time a potential participant is approached and document their decision to participate in the CONTRACT Study. Patients who are screen failures will have their initials, month and year of birth, and reason for failure recorded on the screening log. The screening log will be discussed with the surgical team on a daily basis. Screening logs will be sent to the TM on a weekly basis.

4.5 REGISTRATION/RANDOMISATION PROCEDURES

Once eligibility for the trial is confirmed and informed consent received, patients will be enrolled in the study and randomised to a treatment group (1:1 ratio) via an independent,

web-based system (TENALEA). This online system allows for instant assignment to either the Appendicectomy or Non-Operative treatment group, 24 hours per day.

This service will be provided by the Southampton Clinical Trials Unit, with telephone back-up during office hours (9am – 5pm) on days when the University of Southampton is open.

5 STUDY OBSERVATIONS AND PROCEDURES

5.1 SCREENING PROCEDURES

Children with a diagnosis of acute uncomplicated appendicitis will be identified by the clinical team at the time of diagnosis. Their eligibility for the study will be confirmed by the research nurse at each centre as soon as possible after being informed of the patient.

Clinicians can use a combination of diagnostic tools as part of standard practice to confirm the child's diagnosis, including but not limited to a physical exam, medical history, temperature check, ultrasound, CT scan, blood and pregnancy tests. If any of these are used to diagnose the child, it will be recorded retrospectively on the CRF database once consent and randomisation has been completed. The results of the pregnancy and blood tests will be recorded on the database, specifically total white blood count, C-Reactive Protein and Neutrophils. The Alvarado Score will also be recorded as a clinical descriptor i.e. it will not be used for diagnostic purposes.

5.2 STUDY PROCEDURES

5.2.1 *Randomisation to Discharge*

Informed consent and randomisation should happen within 4 hours of the initial trial discussion. Upon randomisation, the appropriate treatment pathway should be administered immediately, as detailed below.

Non-operative treatment group

This treatment pathway will comprise fluid resuscitation, a minimum of 24 hours broad spectrum intravenous antibiotics (as per local policies), a minimum period of 12 hours 'nil by mouth' and regular clinical review to detect symptoms and signs of significant clinical deterioration including, but not limited to, increasing fever, increasing tachycardia, and increasing tenderness.

Children receiving non-operative treatment, who, in the opinion of the consultant surgeon in charge of their care have clinically deteriorated such that urgent appendicectomy is mandated, will undergo appendicectomy at any stage. A review will be performed at approximately 24 hours following randomisation and any child deemed to have significantly deteriorated will undergo urgent appendicectomy. Those who are stable or clinically improving will continue with non-operative treatment. Those who are not showing clinical signs of improvement at approximately 48 hours following randomisation will undergo urgent appendicectomy. These decision points will be made based on the clinical judgement of the treating consultant as is current practice rather than on any predefined set of criteria for which evidence does not currently exist.

Children who receive an appendicectomy for failure of non-operative treatment will be treated post-operatively according to a standardised treatment regime already in use at

our institutions and identical to that to be used in children in the appendicectomy treatment group (see below). Reason for failure will be recorded on the eCRF database.

After the initial 12-hour period of 'nil by mouth', oral intake will be advanced as tolerated. Children, in whom non-operative treatment is successful, will receive a minimum of 24 hours intravenous antibiotics and then be converted to oral antibiotics (as per local policies) once they are afebrile for 24 hours and tolerating oral intake.

Criteria for discharge home will be: vital signs within normal limits for age, afebrile for ≥ 24 hours, tolerating light diet orally, have adequate oral pain relief and be mobile. They will receive a total course of 10 days antibiotics following randomisation, unless decided otherwise by treating clinician. If more than 10 days oral antibiotics are administered, this will be recorded (including reason). Children who receive non-operative treatment will not be routinely offered interval appendicectomy but will be counselled about the risk of recurrence using best available data.

The following data will be recorded for children randomised to the non-operative treatment arm. This can be collected retrospectively from patient's notes:

- Decision to continue with non-operative treatment – as per clinician review at approximately 24 hours and 48 hours
- Use of antibiotics - both IV and oral
- Use of pain relief - Paracetamol, NSAIDs, Morphine
- Adverse events / effects relating to antibiotic use

For children who received an appendicectomy for failure of non-operative treatment:

- Details of decision to change treatment
- Details regarding the appendicectomy – type of procedure, operative findings, complications (both intra- and post-operative) date, time etc.

Appendicectomy group

Children allocated to appendicectomy will undergo either open or laparoscopic appendicectomy at the surgeon's discretion. The procedure may be performed by a suitably experienced trainee (as is routine current practice) or a consultant. As per current routine practice, a peritoneal microbiology swab will be taken at the time the peritoneum is first opened or from the appendix and any peritoneal fluid sent for microbiological culture. The results of this swab will be recorded.

Participants will receive intravenous antibiotics from the time of randomisation and be treated post-operatively with intravenous antibiotics according to existing institutional protocols. The following recommended regime is intended to guide practice: children with uncomplicated acute appendicitis or a macroscopically normal appendix will receive no further antibiotics; children with a perforated appendix (defined as a faecolith or faecal matter within the peritoneal cavity or visualisation of a hole in the appendix [59]) will continue to receive intravenous antibiotics for a minimum of 3 days, and will receive a minimum total course of antibiotics of 5 days (intravenous and oral). It is not possible to completely 'protocolise' the duration of antibiotics therapy due to anticipated variation in intra-operative findings and in response to treatment. The type of antibiotics used will be identical to those used in the non-operative treatment arm within each centre (see above). Any child failing to respond to these first line antibiotics will be treated as is clinically appropriate with a longer course of antibiotics or a change in antibiotic therapy with choice of antibiotic determined by intra-operative swab or fluid culture.

Post-operatively, children with uncomplicated acute appendicitis or a normal appendix will not routinely have a nasogastric tube, nor a urinary catheter; they will receive oral intake as tolerated after surgery. Criteria for discharge home will be identical to those in the non-operative treatment group.

The following data will be collected for children randomised to the Appendicectomy arm. This can be collected retrospectively from patient's notes:

- Details regarding the appendicectomy – type of procedure, operative findings, complications (both intra- and post-operative) date, time etc.
- Use of antibiotics - both IV and oral
- Use of pain relief - Paracetamol, NSAIDs, Morphine
- Adverse events / effects relating to antibiotic use

5.2.2 Discharge Assessment

Once a decision to discharge the child has been made, a member of the clinical team who has not been directly involved in the child's treatment will be asked to complete a discharge assessment. This assessor will not have prior knowledge of the treatment pathway assigned to the child and will not know which treatment they received. Upon completion of the discharge assessment, they will "guess" which treatment the child received. If the assessor should become unblinded during the assessment, this will be recorded on the CRF database.

All participants, across both treatment groups, will be provided with a discharge pack. This pack will contain a leaflet highlighting concerning symptoms and action to be taken should any of them occur, a patient diary card, a questionnaire booklet and details on how and when to complete. The discharge leaflet will also include advice to contact a member of the medical team at each participating hospital (with relevant contact details) or the participants GP in an emergency and the telephone number of the research nursing team at each site for less urgent concerns. Finally, we will write to the participant's GP to inform them of their patient's inclusion in the study.

Patients in both treatment arms will be followed-up for 6 months following randomisation but we will seek consent for further follow-up including the recording of patient / parent contact information for this purpose. See section 5.3 for more information regarding follow up.

The following data will be collected at discharge:

- Resolution of symptoms – date / time of decision to discharge
- Date and time of first eating
- Total number of cannulae used – antibiotics and fluids
- Outcome of blinded assessment (where possible)
- Adverse events

5.2.3 EMBEDDED QUALITATIVE STUDY OF RECRUITMENT AND TRIAL DESIGN

Qualitative research methods embedded into this feasibility trial as part of the Communication Sub-study to investigate the acceptability to families of the recruitment consultation, trial interventions and wider trial processes, with the aim of optimising informed consent and recruitment. To identify potential barriers to recruitment, and

improve informed consent we will examine the process and experience of CONTRACT at participating sites informed by transcribed audio-recordings of:

1. Recruitment consultations that take place between families, surgeons and research nurses (recruiters) during which information on the trial is provided and discussed before seeking consent for trial entry
2. Follow-up qualitative interviews with families (children and parents) purposively sampled for maximum diversity to include those who accept, decline or withdraw from the trial
3. Follow-up qualitative interviews with recruiters
4. Qualitative interviews with other members of the clinical teams caring for children including nurses and non-participating surgeons

Using data from 1, 2 and 3 above we will compare what was said during recruitment consultations with families' and recruiters' interpretations of these consultations. We will use these comparisons to identify the circumstances, topics or phrases that are associated with difficulties in communicating the study. Qualitative interviews with other members of the clinical teams (4), will examine wider opinions and beliefs about the trial, and the interventions offered in the trial.

Informed by analyses of these data, we will work with recruiters on a dynamic basis to identify strategies to enhance communication about CONTRACT. Findings will be fed back to the TSC and local investigators and suggestions made to change aspects of design, conduct and organisation or training that could be used to improve our planned future trial. Using this iterative process we will enhance and refine recruitment to CONTRACT whilst the trial is in progress [60, 61].

The deliverable will be the cumulative lessons learnt from this work to enhance the information provided to parents and patients (written and video) for a future RCT and inform development of a recruitment 'hints and tips' educational package.

Recording of recruitment conversations

Recruiters will seek verbal permission to audio-record trial recruitment consultations from families whom they approach for CONTRACT. The purpose of the audio-recording these consultations will be briefly outlined and recording device activated if permission is given. At the end of the recruitment consultation recruiters will discuss the qualitative study with the family in more detail and seek signed consent for the audio-recording to be included in the analysis. Recordings from families who decline the inclusion of the audio-recording will be erased at the end of the consultation. Permission to pass the families' contact details to the qualitative researcher will be sought. An experienced qualitative researcher will contact families within a few weeks of discharge from hospital to explain the study further and invite them to be interviewed.

Interviews with children and parents

Semi-structured topic guided interviews with families (parents/carers of children aged 4-15 years and children/young people aged 7-15 years) will usually be carried out within 1-4 weeks after hospital discharge. An information sheet on the interviews will be provided in advance. For face-to-face interviews, a written consent/assent will be sought.

For telephone and Skype interviews, informed consent will be sought verbally – this will involve the researcher reading each aspect of the CONTRACT Communication Sub-Study consent/assent form to participants. The researcher will initial next to each box on the consent form when the participant provides verbal consent, will add the participant name,

date and “telephone/Skype interview” where the signature is required and will post a copy of the form to the participant. Informed consent discussions will be audio recorded for auditing purposes. Other similarly designed studies have previously applied for and obtained ethical approval to obtain consent verbally via telephone or Skype (e.g. REC 15/NW/0913; REC 16/NW/0826).

Children will be interviewed using participatory techniques where appropriate to ensure interviews are engaging and developmentally suitable for children with different levels of maturity. All children will be given the opportunity of being interviewed alone or with their parent present if they prefer.

Interviews with parents and children will investigate:

1. Prior experience of the study interventions; beliefs, expectations and preferences about the interventions before allocation
2. Views on the process of randomisation, and acceptability of the interventions and suggestions for improving the trial design and recruitment process.
3. Outcomes families think are important to measure, and any concerns they have about their child's future well-being.

We are particularly interested in understanding barriers to participation and will interview (subject to informed consent) those who choose not to participate in the trial, or who do not accept treatment allocation at randomisation. Topic guides will be adapted so that they are appropriate for parents and children.

The qualitative interviewers will ensure that interviews are conversational and their pace, sequencing and duration is shaped by participants. To minimise the risk of obtaining generalised or idealised accounts we will routinely review consultation transcripts before the interviews to develop specific prompts as necessary to explore family perceptions of individual recruitment consultations. Topic guides will be periodically revised in the light of the developing analysis to ensure exploration of important but unanticipated issues.

Face-to-face interviews with families will take place at a location of their choosing, usually in their homes, although they will have the option of being interviewed via Skype or telephone if they prefer. Interview topic guides that are used to steer the interviews will mainly comprise open ended questions for participants to describe the recruitment process in their own words and their subsequent experiences of the trial. Interview topic guides will be appropriate to whether they entered and remained in the trial, entered and withdrew or declined.

Interviews with recruiters and wider clinical staff

Interviews with recruiting surgeons and nurses will usually take place after they have conducted at least one CONTRACT recruitment consultation. These interviews, which will usually take place in a private room in participants’ workplaces or by telephone, will follow a similar course to the family interviews, but will be steered by a separate topic guide. For recruiters for whom audio-recorded consultations are available, interviews will be informed by a review of a recording from a recent consultation to explore their goals for the consultation in the light of their approach to communication.

All recruiters and clinical staff will be prompted to describe their views and experiences of CONTRACT. For those with formal roles in recruiting, interviews will explore accounts of deciding which families to approach about the trial. For all staff, interviews will examine experiences of discussing the trial with families at recruitment and subsequently; and what information children and parents require to inform their decision-making. Recruiters’ and

clinical staff members' views about which outcomes are important to measure will also be explored during the interviews.

5.2.4 ASSESSING THE EQUIPOISE OF UK PAEDIATRIC SURGEONS: MIXED METHODS STUDY

We will assess the equipoise and views about a future main trial among paediatric surgeons at non-participating sites using a mixed survey and qualitative design. An online survey will be designed, and will examine surgeons' equipoise over our research question and their potential willingness to invite their patients to be randomised to a trial comparing surgery versus non-operative treatment for acute uncomplicated appendicitis in children. The sample frame will comprise membership lists of the British Association of Paediatric Surgeons (BAPS) and other UK consultant Paediatric surgeons from the 29 UK Specialist Paediatric Surgical centres. Data will be analysed quantitatively. Qualitative interviews with a maximum diversity sub-set (geographical, hospital setting, training level/ research experience, ethnicity) of survey respondents will contextualise the survey responses and explore what knowledge has informed their potential willingness or reluctance to invite patients to be randomised, their position in relation to equipoise and what other considerations might influence their involvement in a future trial. We will further explore suggestions regarding the design of the future trial, obstacles to be overcome and important outcomes in 2 focus groups. Focus group participants will be selected based on survey responses to create groups with diverse views to allow us to explore a wide range of opinion.

5.2.5 EMBEDDED HEALTH ECONOMICS STUDY

We will collect cost data during the in-patient phase of treatment and also identify costs associated with healthcare resource use and societal costs (e.g. days off school, parental days off work) during the 6 month follow-up period using a modified version of the Client Service Receipt Inventory (CSRI) questionnaire and the patient diary card. The patient diary card will cover the 2 week period immediately following discharge while the CSRI will be collected at the 6 week and 6 month follow up appointments.

To enable detection of any effect of our intervention on QoL we will collect data using preference-based quality of life measures. We will assess the appropriateness of using the QALY framework in the future RCT, as well as testing and identifying the most suitable QoL instrument. The proposed measures are the child friendly version of the EQ-5D 5L and the CHU-9D, a new quality of life measure specifically designed for use in studies with children [68, 69]. The EQ-5D-5L comprises the same 5 dimensions as the EQ-5D-3L but 5 levels of severity, which is considered to significantly increase reliability and sensitivity (discriminatory power) [87, 88].

Both measures will be obtained from parental/carer proxy responses. Children aged 7 and over can also complete these if they wish. We will collect both QoL measures at baseline; discharge; 2 weeks (provided to patient at discharge), to determine any short term difference in QoL that may be missed at 6 week follow-up); 6 weeks; 3 months; and 6 months, to define the most appropriate timing of assessment in relation to other health outcomes. The baseline questionnaires should be completed before the patient and family know their treatment allocation.

5.3 FOLLOW UP

Follow-up appointments will take place at 6 weeks, 3 months and 6 months following discharge in the outpatient clinic or Clinical Research Facility at each participating centre. There is also the potential for the 3 month and 6 month appointments to be completed over the phone if a face-to-face appointment is not possible. The follow up appointments should be completed no earlier than 1 week before the projected visit date, and no later than 2 weeks after the projected visit date.

Data will be collected prospectively to ensure high accuracy. These visits will ensure completeness of the dataset collected, in particular time to return to daily activities, recurrent appendix-related problems (including unexplained abdominal pain and recurrence) and resource use data.

The following data will be collected at all follow up appointments:

- QoL questionnaires (EQ-5D and CHU-9D)
- CSRI (6 week and 6 month appointments only)
- Readmission relating to appendicitis / Recurrent appendicitis
- Health service resource use relating to appendicitis
- Complications since discharge

Data specifically collected at 6 week follow up appointment:

- Histology findings for children who received an appendicectomy
- Outcome of physical exam (if completed as part of standard care)

We will also seek consent from parents to contact them at yearly intervals by telephone / e-mail to find out if their child has had recurrent appendicitis during a longer duration of follow-up, up to a maximum of 5 years. We will request consent to store personal data (telephone number and e-mail address) securely for the purposes of this study only. This activity is outside of the current funding remit.

5.4 DEVIATIONS AND SERIOUS BREACHES

Any study protocol deviations/violations and breaches of Good Clinical Practice occurring at sites should be reported to the SCTU and the local R&D Office immediately. SCTU will then advise of and/or undertake any corrective and preventative actions as required.

5.5 STUDY DISCONTINUATION

In consenting to the study, participants have consented to the study intervention, follow-up and data collection. Participants may be discontinued from the study procedures at any time.

5.5.1 Reasons for study discontinuation

Participants may be discontinued from the study in the event of:

- Clinical decision, as judged by the Principal Investigator or Chief Investigator
- Withdrawal of informed consent (participant's decision to withdraw for any reason)
- Serious adverse event which, in the opinion of the investigator, indicates that continued participation in the study is not in the best interest of the participant

- Any clinical adverse event, laboratory abnormality or intercurrent illness which, in the opinion of the investigator, indicates that continued participation in the study is not in the best interest of the participant
- Participant non-compliance

Full details of the reason for study discontinuation should be recorded in the eCRF and medical record.

5.6 WITHDRAWAL

The participant / legal representative is free to withdraw consent from the study at any time without providing a reason.

If a participant withdraws from the trial prior to receiving the allocated intervention they will be treated as determined by the consultant in charge of the child's care.

Investigators should explain to patients the value of remaining in study follow-up and allowing this data to be used for trial purposes. Where possible, patients who have withdrawn from study treatment should remain in follow-up as per the trial schedule. If patients additionally withdraw consent for this, they should revert to standard clinical care as deemed by the responsible clinician. It would remain useful for the study team to continue to collect standard follow-up data and unless the patient explicitly states otherwise, follow-up data will continue to be collected.

Details of study discontinuation (date, reason if known) should be recorded in the eCRF and medical record.

5.7 PROHIBITED AND RESTRICTED THERAPIES DURING THE STUDY

None

5.8 BLINDING AND PROCEDURES FOR EMERGENCY UNBLINDING

Due to the nature of the interventions in this study there will be no blinding of participants or investigators.

6 SAFETY

6.1 DEFINITIONS

Adverse Event (AE): any untoward medical occurrence in a participant or clinical study participant which does not necessarily have a causal relationship with study treatment or participation.

An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment or participation (regardless of causality assessments).

Serious Adverse Event (SAE) or Serious Adverse Reaction is any untoward medical occurrence or effect that :

- **Results in death**
- **Is life-threatening** – *refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe*
- **Requires hospitalisation, or prolongation of existing hospitalisation**
- **Results in persistent or significant disability or incapacity**
- **Is a congenital anomaly or birth defect**
- Other important medical events***.

*‘life-threatening’ in the definition of ‘serious’ refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.

**Hospitalisation is defined as an inpatient admission, regardless of length of stay, even if the hospitalisation is a precautionary measure for continued observation. Hospitalisations for a pre-existing condition, including elective procedures that have not worsened, do not constitute an SAE.

***Other important medical events May also be considered serious if they jeopardise the participant or require an intervention to prevent one of the above consequences.

Note: It is the responsibility of the PI or delegate to grade an event as ‘not serious’ (AE) or ‘serious’ (SAE).

6.2 SERIOUSNESS

All adverse events that fulfil the criteria definition of ‘serious’ in protocol section 6.1, must be reported to SCTU using the Serious Adverse Event Report Form – Non-CTIMP. All SAEs must be reported immediately by the PI at the participating centre to the SCTU unless the SAE is specified as not requiring reporting (see section 6.2.1 below).

6.2.1 Exceptions:

For the purposes of this study, the following SAEs **do not** require reporting to SCTU using the Serious Adverse Event Report Form – Non-CTIMP:

- Prolonged hospital stay due to treatment of appendicitis
- Re-admission to hospital for complication of either treatment and/or appendicitis
- Admission to hospital for treatment of recurrent appendicitis
- Hospitalisations for elective treatment of a pre-existing condition

These events should be reported on eCRF as AEs.

6.3 CAUSALITY

A complete assessment of the causality must always be assessed by a medically qualified doctor who is registered on the delegation of responsibility log; this is usually the investigator.

If any doubt about the causality exists the local investigator should inform the SCTU who will notify the Chief Investigator. Other clinicians may be asked for advice in these cases.

Relationship	Description
Unrelated	There is no evidence of any causal relationship
Unlikely	There is little evidence to suggest there is a causal relationship (e.g. the event did not occur within a reasonable time after administration of the study treatment). There is another reasonable explanation for the event (e.g. the participant's clinical condition, other concomitant treatment).
Possibly	There is some evidence to suggest a causal relationship (e.g. because the event occurs within a reasonable time after administration of the study treatment). However, the influence of other factors may have contributed to the event (e.g. the participant's clinical condition, other concomitant treatments).
Probably	There is evidence to suggest a causal relationship and the influence of other factors is unlikely.
Definitely	There is clear evidence to suggest a causal relationship and other possible contributing factors can be ruled out.

In the case of discrepant views on causality between the Investigator and others, SCTU will classify the event as per the worst case classification I and where applicable the Ethics Committee will be informed of both opinions within the required timelines.

6.4 EXPECTEDNESS

Expectedness assessments are made against the list of expected events below:

6.4.1 Expected Adverse Events:

- A. Related to both treatment groups:
 - (i) Abdominal pain or recurrent abdominal pain post treatment
 - (ii) Fever
 - (iii) Vomiting
 - (iv) Diarrhoea/loose stool
- B. Related to operative management:
 - (i) Intra-operative damage to surrounding anatomical structures including but not limited to bowel loops, urethra, vessels, Fallopian tubes, ovaries
 - (ii) Intra-operative finding of perforated appendicitis
 - (iii) Intra-operative bleeding requiring blood transfusion
 - (iv) Post-operative small bowel adhesions
 - (v) Post-operative intestinal obstruction
 - (vi) Post-operative hypertrophic scar (cheloid)
 - (vii) Intra-abdominal or pelvic abscess formation
 - (viii) Surgical Site Infection
 - (ix) Wound Infection or Dehiscence
 - (x) Recurrent abdominal pain
- C. Related to non-operative management:
 - (i) Adverse events related to antibiotic use as per product monographs
 - (ii) Non-response to non-operative management (requiring appendicectomy)
 - (iii) Recurrent abdominal pain

(iv) Recurrent appendicitis

The nature or severity of should be considered when making the assessment of expectedness. If these factors are not consistent with the current information available then the AE should be recorded as 'unexpected'.

6.5 REPORTING PROCEDURES

All Adverse Events are to be recorded in the participant's medical notes. AEs should be graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

Depending on the nature of the event, the appropriate reporting procedures below should be followed. A flowchart will be provided to aid in the reporting procedures.

6.5.1 Reporting Details

A SAE for Non-CTIMPs Form should be completed for all SAEs and faxed to SCTU within 24 hours of site becoming aware of the event.

Complete the SAE form and fax or email a scanned copy of the form with as many details as possible to the SCTU together with anonymised relevant treatment forms and investigation reports.

Or

Contact the SCTU by phone for advice and then fax or email a scanned copy of the completed SAE form.

SAE REPORTING CONTACT DETAILS

*Please email or fax a copy of the SAE form to
SCTU within 24 hours of becoming aware of the event*

Fax: 0844 774 0621 or Email: ctu@soton.ac.uk

FAO: Quality and Regulatory Team

For further assistance: Tel: 023 8120 4138 (Mon to Fri 09:00 – 17:00)

Additional information should be provided as soon as possible if the event has not resolved at the time of reporting.

6.5.2 Follow Up and Post- study SAEs

The reporting requirement for SAEs affecting participants applies for all events occurring up to 6 months after initial hospital discharge.

All unresolved adverse events should be followed by the investigator until resolved, the participant is lost to follow-up, or the adverse event is otherwise explained. At the last scheduled visit, the investigator should instruct each participant to report any subsequent event(s) that the participant, or the participant's general practitioner, believes might reasonably be related to participation in this study. The investigator should notify the study

sponsor of any death or adverse event occurring at any time after a participant has discontinued or terminated study participation that may reasonably be related to this study.

6.5.3 *Non-serious AEs*

All adverse events should be recorded in the relevant eCRF and submitted to SCTU. The window for reporting of adverse events begins at the time of informed consent and finishes when the patient reaches the end of study.

6.5.4 *Pre-existing Conditions*

Medically significant pre-existing conditions (prior to informed consent) should not be reported as an AE unless the conditions worsens during the trial. The condition, however, must be reported on the Medical History eCRF. Any adverse events which occur after informed consent taken should be recorded on the AE eCRF as per safety reporting section.

6.5.5 *Serious Adverse Events*

All SAEs should be reported within 24 hours of the local site becoming aware of the event. The SAE Non-CTIMP Form asks for nature of event, date of onset, severity, corrective therapies given, outcome, causality (i.e. unrelated, unlikely, possible, probably, definitely) and expectedness. The responsible investigator should assign the causality and expectedness of the event with reference to the events listed in Section 6.4.1. The event term should be in accordance with the latest version of MedDRA and grades given in accordance with the NCI CTCAE v4.03, Additional information should be provided as soon as possible if the event has not resolved at the time of reporting.

6.6 SCTU RESPONSIBILITIES FOR SAFETY REPORTING TO REC

SCTU is responsible for onward reporting of:

- Information about SAEs which are both related to the research procedures and are unexpected, to the REC within 15 days of the sponsor becoming aware of the event
- All safety information to the REC in the annual progress report

7 STATISTICS AND DATA ANALYSES

7.1 METHOD OF RANDOMISATION

Patients enrolled in the study will be randomised to groups (1:1 ratio), online allowing instant assignment to treatment group 24 hours per day. This service will be provided by the Southampton Clinical Trials Unit with telephone back-up during office hours (9am – 5pm) on days when the University of Southampton is open. Minimisation will be used to ensure similarity between the groups in factors that may affect diagnostic accuracy and outcome of treatment.

7.2 SAMPLE SIZE

We will recruit participants from 3 centres for 12 months. Each centre treats 80-100 children per year with acute appendicitis of which we estimate at least 130 will be eligible. Assuming 40-50% will be recruited (i.e. 52-65 participants in our feasibility RCT) we will be able to estimate a true 40% recruitment rate with a 95% confidence interval (CI) of 31% to

49% and a true 50% recruitment rate with a 95% CI of 41% to 59%. We estimate 52-65 participants in our feasibility RCT which will be adequate to test treatment pathway procedures, data collection methods and loss to follow-up.

For our embedded qualitative work related to recruitment, we will recruit until we reach data saturation which we estimate will include analysing approximately 40 recruitment consultations, and interviewing 20-30 families, and 20-25 surgeons and other healthcare professionals.

7.3 INTERIM ANALYSIS

No interim analyses are planned.

7.4 STATISTICAL ANALYSIS PLAN (SAP)

CLINICAL TRIAL DATA ANALYSIS

Data analysis will be performed by the study statistician who will be blinded to treatment allocation by the use of coded data. As this is a feasibility study, all analyses will be treated as preliminary and exploratory and will be mainly descriptive. Feasibility outcomes (number of eligible patients, recruitment and retention rates, reasons for non-participation, success of blinding), treatment outcomes and complications will be presented by simple summary statistics with 95% confidence intervals.

Clinical outcome measures will be compared between treatment groups in an exploratory analysis, and variability estimates will be used to inform the sample size for a future definitive trial. The study will be reported in accordance with the CONSORT 2010 statement.

ANALYSIS OF DATA ARISING FROM EMBEDDED QUALITATIVE STUDY

Consultations and interviews will be digitally audio-recorded and then uploaded for transcription by a professional transcription service via a secure system. Transcripts will be pseudoanonymised before analysis by removing details such as person and place names and replacing these with codes.

Analysis of recruitment consultation data

We will analyse the recruitment consultations, by listening to these as well as working with the transcripts, documenting the interaction between recruiter and potential participant and exploring information provision, communication techniques, intervention preferences, and trial participation decisions. If analyses of the audio-recordings suggest that recruitment difficulties are potentially linked to communication during the recruitment consultation, this will be documented, fed back to the local PIs and training implemented. This may include simply providing feedback to the recruiter on altering particular words used to describe the trial/interventions or may include suggestions on how to make the consultation more balanced in terms of information given on the different interventions. It may also involve feedback to explore families' preferences for the interventions. We will also assess the equipoise and views of surgeons recruiting to the trial, and investigate key ways in which their views differ from non-participating surgeons.

Analysis of recruitment consultations will use content analytic methods to describe in a structured manner what was said by whom and how often in the audio-recordings of recruitment sessions. More flexible constant comparison methods will be used to identify common or divergent themes, particularly focusing on the impact of statements by the recruiter on parent responses and views. Thematic analysis will be used to focus in great detail on certain sections of the transcripts, for example, in the interactions during which randomisation is offered. We will document the percentage recruited of those eligible using screening logs. Families who decline randomisation or do not accept their randomisation

allocation will be noted. We will link these findings with qualitative data from the interviews where patients discuss the acceptability of trial methodology to determine the feasibility and acceptability of a full trial.

Analysis of interview data

We will analyse interview data for evidence of the needs, priorities and goals of families in relation to recruitment, randomisation, intervention preferences, their experiences and acceptability of the intervention and views regarding which outcomes are important. Analysis of interviews with surgeons and nurses at study sites will focus on their perceptions and experiences of recruitment, as well as their perceptions of the interventions and which outcomes are important. Analysis of interviews and focus groups with UK paediatric surgeons at non study sites will focus on perceptions of the interventions and other influences on their willingness to recruit patients to a future RCT, as well as their views on the design of such a trial.

Analysis of all interview data will draw on the principles of the constant comparative method and thematic analysis. One member of the research team will lead a process of 'cycling' between the developing analysis and new data. Other members of the qualitative study team (including at least one surgeon) will develop and test the analysis by periodic discussion and independent analyses of a proportion of transcripts to compare coding and findings.

Initially, each transcript will be read several times by the lead analyst, before developing open codes to describe each relevant unit of meaning, although coding will occur at multiple levels, from detailed descriptions of communication and experiences of the trial, to the general orientation of participants towards clinical research. Through comparison within and across the transcripts, the open codes will be developed into categories to reflect and test the developing analysis.

The categories will be organised into a framework to code and index the transcripts using QSR NVivo software. The framework categories will be continually checked and modified to ensure an adequate 'fit' with the data, whilst also accounting for variation in the data and 'deviant' cases. The categories and the assignment of data to them will be checked by a second member of the team. Our analytic approach will be informed by writings on quality in qualitative research [70].

We will not take participants' accounts only at face value, rather our approach will be interpretive and consider both latent and manifest aspects of the data (e.g. what we can learn from the way that participants talk as well as the explicit content).

HEALTH ECONOMICS ANALYSIS PLAN (HEAP)

A bottom-up micro-costing approach will be adopted to identify key cost drivers, which is characterised by the identification of patient-specific resource use and national tariffs as unit costs, and will be compared to the HRG tariff to identify the most appropriate costing method for the future definitive trial. In addition to secondary care, primary care and patient born resource use will be identified. This will lead to the design of a modified version of the CSRI questionnaire. The Client Service Receipt Inventory (CSRI) is a research instrument developed to collect information of service utilisation and resource use patterns. One of the greatest strengths of this instrument is its adaptability. The finalised version of the CSRI will be piloted during the study and will be used in our future RCT. Descriptive statistics will be presented for costs, presenting the main cost drivers, and for QoL in QALY terms. At each occasion, inferences will be made as to the most appropriate way of measuring and collecting data for the economic analysis for application within the definitive trial. The feasibility and acceptability of data collection tools will be measured by completion rates and quality of data. The analysis of health economic data for this feasibility

trial is focussed on enabling cost effectiveness analysis and cost utility analysis of our future RCT.

8 REGULATORY

8.1 CLINICAL TRIAL AUTHORISATION

This study is not considered to be a clinical trial of a medicinal product, so clinical trial authorisation from the UK Competent Authority the Medicines and Healthcare products Regulatory Agency (MHRA) is not applicable.

9 ETHICAL CONSIDERATIONS

The study will be conducted in accordance with the recommendations for physicians involved in research on human participants adopted by the 18th World Medical Assembly, Helsinki 1964 as revised and recognised by governing laws and EU Directives. Each participant's consent to participate in the study should be obtained after a full explanation has been given of treatment options, including the conventional and generally accepted methods of treatment. The right of the participant to refuse to participate in the study without giving reasons must be respected.

After the participant has entered the study, the clinician may give alternative treatment to that specified in the protocol, at any stage, if they feel it to be in the best interest of the participant. However, reasons for doing so should be recorded and the participant will remain within the study for the purpose of follow-up and data analysis according to the treatment option to which they have been allocated. Similarly, the participant remains free to withdraw at any time from protocol treatment and study follow-up without giving reasons and without prejudicing their further treatment.

9.1 SPECIFIC ETHICAL CONSIDERATIONS

1. Participants will be randomised to a novel care pathway.

Although antibiotic treatment has not undergone rigorous evaluation for efficacy and safety, the existing literature supports the concept that non-operative treatment of acute uncomplicated appendicitis in children is safe [1-6]. Families will be fully informed that the clinical outcomes of this pathway are being investigated as part of this study, are of unproven efficacy but are considered safe.

Regular clinical review will enable early identification of such patients, thereby minimising risk of complications or harm and minimising the adverse effects of unsuccessful treatment. Some patients/parents may be concerned that delay in appendicectomy may increase the rate of perforation and adverse events. However this is not borne out by the literature on large numbers of adult patients [7, 8, 76, 77] and participants will be counselled accordingly. The safety of participants will be further enhanced by the formation of the DMSC as outlined above.

In addition, children in the non-operative treatment group will continue to be at theoretical risk of recurrence of appendicitis. Whilst the risk of recurrence is low, the child and their families will be fully informed of this risk. We will seek permission from these families to hold their personal details in a secured registry and to contact them in the future to determine if they have had a recurrence.

2. Enrolment of children

The main study will only enrol children. Informed consent will be taken from the child's parents with the child's assent if appropriate. The investigators all have experience of

recruiting children for research studies including randomised studies and those involving a complex intervention. Consent will be taken by professionals who have received appropriate training in taking research consent from children and their parents.

3. Short timeframe within which participants will be asked to decide whether to participate.
We are sensitive to the need for participants and families to be given adequate time to consider the study yet there is also a need for a decision to be made within a short period of time. Whilst appendicectomy is not typically a true surgical emergency it is considered an urgent procedure. The consent process is therefore 'time-constrained' rather than truly emergent. Participants will be made aware of this and consent will be obtained within a maximum of 4 hours of first discussion of the study. The research process will never impede on provision of safe and effective patient care.

9.2 ETHICAL APPROVAL

The study protocol has received the favourable opinion of a Research Ethics Committee or Institutional Review Board (IRB) in the approved national participating countries.

9.3 INFORMED CONSENT PROCESS

Informed consent is a process that is initiated prior to an individual agreeing to participate in a study and continues throughout the individual's participation. In obtaining and documenting informed consent, the investigator should comply with applicable regulatory requirements and should adhere to the principles of GCP.

Discussion of objectives, risks and inconveniences of the study and the conditions under which it is to be conducted are to be provided to the participant by appropriately delegated staff with knowledge in obtaining informed consent with reference to the patient information leaflet. This information will emphasise that participation in the trial is voluntary and that the participant may withdraw from the trial at any time and for any reason. The participant will be given the opportunity to ask any questions that may arise and provided the opportunity to discuss the study with family members, friend or an independent healthcare professional outside of the research team and time to consider the information prior to agreeing to participate.

9.4 CONFIDENTIALITY

SCTU will preserve the confidentiality of participants taking part in the study. The investigator must ensure that participant's anonymity will be maintained and that their identities are protected from unauthorised parties. On CRFs participants will not be identified by their names, but by an identification code.

10 SPONSOR

SCTU, Chief Investigator and other appropriate organisations have been delegated specific duties by the Sponsor and this is documented in the trial task allocation matrix.

The duties assigned to the study sites (NHS Trusts or others taking part in this study) are detailed in the Non-Commercial Agreement.

10.1 INDEMNITY

For NHS sponsored research HSG (96) 48 reference no.2 applies. If there is negligent harm during the clinical study when the NHS body owes a duty of care to the person harmed,

NHS Indemnity covers NHS staff, medical academic staff with honorary contracts, and those conducting the study. NHS Indemnity does not offer no-fault compensation and is unable to agree in advance to pay compensation for non-negligent harm. Ex-gratia payments may be considered in the case of a claim.

10.2 FUNDING

NETSCC HTA are funding this study.

Site payments

The payments assigned to the study sites (NHS Trusts or others taking part in this study) are detailed in the Non-Commercial Agreement.

This study is adopted onto the NIHR portfolio. This enables Trusts to apply to their comprehensive local research network for service support costs, if required

Participant payments

Participants will not be paid for participation in this study.

10.3 AUDITS AND INSPECTIONS

The study may be participant to inspection and audit by UHS (under their remit as Sponsor), SCTU (as the Sponsor's delegate) and other regulatory bodies to ensure adherence to the principles of GCP, Research Governance Framework for Health and Social Care, applicable contracts/agreements and national regulations.

11 STUDY OVERSIGHT GROUPS

The day-to-day management of the study will be co-ordinated through the SCTU and oversight will be maintained by the Study Management Group, the Trial Steering Committee and the Data Monitoring and Ethics Committee.

11.1 STUDY MANAGEMENT GROUP (SMG)

The SMG is responsible for overseeing progress of the study, including the trial, the Qualitative subgroup and survey and COS subgroup. The Chair of the SMG will be the Chief Investigator of the study.

The Qualitative Subgroup will meet every 2 months to input to these work streams and for quality assurance. They will report on progress back to the SMG following each meeting.

The survey work and the COS development subgroup will meet every 2 months and report back to the SMG after each meeting.

The CONTRACT SMG charter defines the membership, terms of reference, roles, responsibilities, authority, decision-making and relationships of the SMG, including the timing of meetings, frequency and format of meetings and relationships with other trial committees.

11.2 TRIAL STEERING COMMITTEE (TSC)

The TSC acts as the oversight body on behalf of the Sponsor and Funder. The TSC will meet prior to recruitment into the trial and every 3 months during the recruitment period to the clinical trial. The TSC will oversee the conduct of the clinical trial and review any substantial

issues regarding the trial. In the event of any patient safety concern raised by the DMSC, the TSC will advise the SMG and the Sponsor on the continuation of the trial. The TSC will determine any rules for recommending that recruitment into the trial cease on the basis of patient safety or ethical concerns at their initial meeting. Membership of the TSC shall comprise an independent (to the study and any of the participating institutions) chair who will be a surgeon, 2 further independent members (one paediatric surgeon and one paediatrician) and a PPI representative.

The CONTRACT TSC charter defines the membership, terms of reference, roles, responsibilities, authority, decision-making and relationships of the TSC, including the timing of meetings, frequency and format of meetings and relationships with other trial committees.

11.3 DATA MONITORING AND SAFETY COMMITTEE (DMSC)

The clinical trial will have an independent Data Monitoring and Safety Committee (DMSC) whose primary function will be to monitor trial data for ethical or safety reasons. The DMSC will meet twice more on a planned basis (after 6 months recruitment to the clinical trial and at the end of the trial). Additional meetings will be convened as required or as directed by the TSC or CI. Any patient who 'fails' non-operative treatment within the trial and undergoes appendicectomy will be reported to the Trial Manager (TM) within 48 hours of appendicectomy. The TM will inform the TSC chairperson and will pass the clinical data relating to this patient to them. The TSC chair will hold responsibility for determining whether to ask the DMSC to meet and review the data from that patient. The DMSC will subsequently advise the TSC on their findings including an assessment of whether it is acceptable to continue to recruit patients. Membership of the DMSC will comprise a chair and at least 2 further members with the necessary clinical expertise, all of whom will be independent to the trial.

12 DATA MANAGEMENT

Participant data will be entered remotely at site and retained in accordance with the Data Protection Act (1988). The PI is responsible for ensuring the accuracy, completeness, and timeliness of the data entered.

The participant data is pseudo anonymised by assigning each participant a participant identifier code which is used to identify the participant during the study and for any participant- specific clarification between SCTU and site. The site retains a participant identification code list which is only available to site staff.

The Informed Consent Form will specify the participant data to be collected and how it will be managed or might be shared; including handling of all Patient Identifiable Data (PID) and sensitive PID adhering to relevant data protection law.

Trained personnel with specific roles assigned will be granted access to the electronic case report forms (eCRF). eCRF completion guidelines will be provided to the investigator sites to aid data entry of participant information.

Only the Investigator and personnel authorised by them should enter or change data in the eCRFs. When requested, laboratory data must be transcribed, with all investigator observations entered into the eCRF. The original laboratory reports must be retained by the Investigator for future reference.

A Data Management Plan (DMP) providing full details of the study specific data management strategy for the trial will be available and a Trial Schedule with planned and actual milestones, CRF tracking and central monitoring for active trial management created.

Data queries will either be automatically generated within the eCRF, or manually raised by the study team, if required. All alterations made to the eCRF will be visible via an audit trail which provides the identity of the person who made the change, plus the date and time.

At the end of the study after all queries have been resolved and the database frozen, the PI will confirm the data integrity by electronically signing all the eCRFs. The eCRFs will be archived according to SCTU policy and a PDF copy including all clinical and Meta data returned to the PI for each participant.

Data may be requested from the Data Access Committee at SCTU. Request will be considered on a monthly basis.

13 MONITORING

13.1 CENTRAL MONITORING

Data stored at SCTU will be checked for missing or unusual values (range checks) and checked for consistency within participants over time. Any suspect data will be returned to the site in the form of data queries. Data query forms will be produced at SCTU from the trial database and sent either electronically or through the post to a named individual (as listed on the site delegation log). Sites will respond the queries providing an explanation/resolution to the discrepancies and return the data query forms to SCTU. The forms will then be filed along with the appropriate CRFs and the appropriate corrections made on the database. There are a number of monitoring features in place at SCTU to ensure reliability and validity of the trial data, which are detailed in the trial monitoring plan.

The DMSC also have responsibility for specific central monitoring activities, as described in protocol section 11.3.

13.2 CLINICAL SITE MONITORING

There may be monitoring visits as and when required.

Source Data Verification

On receipt of a written request from SCTU, the PI will allow the SCTU direct access to relevant source documentation for verification of data entered onto the eCRF (taking into account data protection regulations). Access should also be given to study staff and departments (e.g. pharmacy).

The participants' medical records and other relevant data may also be reviewed by appropriate qualified personnel independent from the SCTU appointed to audit the study, including representatives of the Competent Authority. Details will remain confidential and participants' names will not be recorded outside the study site.

13.3 SOURCE DATA

Source documents are where data are first recorded, and from which participants' CRF data are obtained. These include, but are not limited to, hospital records (from which medical history and previous and concurrent medication may be summarised), clinical and office

charts, laboratory and pharmacy records, diaries, microfiches, radiographs, and correspondence.

14 RECORD RETENTION AND ARCHIVING

Study documents will be retained in a secure location during and after the trial has finished.

The PI or delegate must maintain adequate and accurate records to enable the conduct of the study to be fully documented and the study data to be subsequently verified. After study closure the PI will maintain all source documents and study related documents. All source documents will be retained for a period of 10 years following the end of the study.

Sites are responsible for archiving the ISF and participants' medical records.

The Sponsor is responsible for archiving the TMF and other relevant documentation.

15 PUBLICATION POLICY

Data from all centres will be analysed together and published as soon as possible.

Individual investigators may not publish data concerning their patients that are directly relevant to questions posed by the trial until the Study Management Group (SMG) has published its report. The SMG will form the basis of the Writing Committee and advise on the nature of publications. All publications shall include a list of investigators, and if there are named authors, these should include the Chief Investigator, Co-Investigators, Trial Manager, and Statistician(s) involved in the trial. Named authors will be agreed by the CI and Director of SCTU. If there are no named authors then a 'writing committee' will be identified.

16 REFERENCES

- (1) Minneci PC, Sulkowski JP, Nacion KM, et al (2014) Feasibility of a nonoperative management strategy for uncomplicated acute appendicitis in children. *J Am Coll Surg* 219:272-279
- (2) Abes M, Petik B, Kazil S (2007) Nonoperative treatment of acute appendicitis in children. *J Pediatr Surg* 42:1439-1442
- (3) Armstrong J, Merritt N, Jones S, Scott L, Butter A (2014) Non-operative management of early, acute appendicitis in children: is it safe and effective? *J Pediatr Surg* 49:782-785
- (4) Gorter RR, van der Lee JH, Cense HA, et al (2015) Initial antibiotic treatment for acute simple appendicitis in children is safe: Short-term results from a multicenter, prospective cohort study. *Surgery* 157:916-923
- (5) Svensson JF, Patkova B, Almstrom M, et al (2014) Nonoperative Treatment With Antibiotics Versus Surgery for Acute Nonperforated Appendicitis in Children: A Pilot Randomized Controlled Trial. *Ann Surg*
- (6) Steiner Z, Buklan G, Stackiewicz R, Gutermacher M, Erez I (2015) A role for conservative antibiotic treatment in early appendicitis in children. *J Pediatr Surg*
- (7) Bhangu A (2014) Safety of short, in-hospital delays before surgery for acute appendicitis: multicentre cohort study, systematic review, and meta-analysis. *Ann Surg* 259:894-903
- (8) Ingraham AM, Cohen ME, Bilimoria KY, et al (2010) Effect of delay to operation on outcomes in adults with acute appendicitis. *Arch Surg* 145:886-892
- (9) Tiboni S, Bhangu A, Hall NJ (2014) Outcome of appendicectomy in children performed in paediatric surgery units compared with general surgery units. *Br J Surg* 101:707-714
- (10) Collins HL, Almond SL, Thompson B, et al (2010) Comparison of childhood appendicitis management in the regional paediatric surgery unit and the district general hospital. *J Pediatr Surg* 45:300-302
- (11) Whisker L, Luke D, Hendrickse C, Bowley DM, Lander A (2009) Appendicitis in children: a comparative study between a specialist paediatric centre and a district general hospital. *J Pediatr Surg* 44:362-367
- (12) St Peter SD, Tsao K, Spilde TL, et al (2008) Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trial. *J Pediatr Surg* 43:981-985

- (13) Varadhan KK, Neal KR, Lobo DN (2012) Safety and efficacy of antibiotics compared with appendectomy for treatment of uncomplicated acute appendicitis: meta-analysis of randomised controlled trials. *BMJ* 344:e2156
- (14) Lee SL, Stark R, Yaghoubian A, Shekherdimian S, Kaji A (2011) Does age affect the outcomes and management of pediatric appendicitis? *J Pediatr Surg* 46:2342-2345
- (15) Mizrahi I, Mazeh H, Levy Y, et al (2012) Comparison of pediatric appendectomy outcomes between pediatric surgeons and general surgery residents. *J Surg Res*
- (16) BOWERS WF, HUGHES CW, BONILLA KB (1958) The treatment of acute appendicitis under suboptimal conditions. *U S Armed Forces Med J* 9:1545-1557
- (17) Vons C, Barry C, Maitre S, et al (2011) Amoxicillin plus clavulanic acid versus appendectomy for treatment of acute uncomplicated appendicitis: an open-label, non-inferiority, randomised controlled trial. *Lancet* 377:1573-1579
- (18) Styrud J, Eriksson S, Nilsson I, et al (2006) Appendectomy versus antibiotic treatment in acute appendicitis. a prospective multicenter randomized controlled trial. *World J Surg* 30:1033-1037
- (19) Hansson J, Korner U, Khorram-Manesh A, Solberg A, Lundholm K (2009) Randomized clinical trial of antibiotic therapy versus appendectomy as primary treatment of acute appendicitis in unselected patients. *Br J Surg* 96:473-481
- (20) Eriksson S, Granstrom L (1995) Randomized controlled trial of appendectomy versus antibiotic therapy for acute appendicitis. *Br J Surg* 82:166-169
- (21) Mason RJ (2008) Surgery for appendicitis: is it necessary? *Surg Infect (Larchmt)* 9:481-488
- (22) Ansaloni L, Catena F, Coccolini F, et al (2011) Surgery versus conservative antibiotic treatment in acute appendicitis: a systematic review and meta-analysis of randomized controlled trials. *Dig Surg* 28:210-221
- (23) Liu K, Fogg L (2011) Use of antibiotics alone for treatment of uncomplicated acute appendicitis: a systematic review and meta-analysis. *Surgery* 150:673-683
- (24) Salminen P, Paajanen H, Rautio T, et al (2015) Antibiotic Therapy vs Appendectomy for Treatment of Uncomplicated Acute Appendicitis: The APPAC Randomized Clinical Trial. *JAMA* 313:2340-2348
- (25) Turhan AN, Kapan S, Kutukcu E, Yigitbas H, Hatipoglu S, Aygun E (2009) Comparison of operative and non operative management of acute appendicitis. *Ulus Travma Acil Cerrahi Derg* 15:459-462
- (26) Mason RJ (2011) Appendicitis: is surgery the best option? *Lancet* 377:1545-1546
- (27) Mason RJ, Moazzez A, Sohn H, Katkhouda N (2012) Meta-analysis of randomized trials comparing antibiotic therapy with appendectomy for acute uncomplicated (no abscess or phlegmon) appendicitis. *Surg Infect (Larchmt)* 13:74-84
- (28) Fitzmaurice GJ, McWilliams B, Hurreiz H, Epanomeritakis E (2011) Antibiotics versus appendectomy in the management of acute appendicitis: a review of the current evidence. *Can J Surg* 54:307-314
- (29) Svensson JF, Hall NJ, Eaton S, Pierro A, Wester T (2012) A review of conservative treatment of acute appendicitis. *Eur J Pediatr Surg* 22:185-194
- (30) Wilms IM, de Hoog DE, de Visser DC, Janzing HM (2011) Appendectomy versus antibiotic treatment for acute appendicitis. *Cochrane Database Syst Rev* :CD008359
- (31) Appendectomy versus antibiotic treatment for acute appendicitis. <http://www.library.nhs.uk/duets/ViewResource.aspx?resID=411632> 2015 [cited 2015 Sep 10];
- (32) Svensson JF, Hall NJ, Eaton S, Pierro A, Wester T (2012) A review of conservative treatment of acute appendicitis. *Eur J Pediatr Surg* 22:185-194
- (33) Barsness KA, Bensard DD, Partrick DA, et al (2004) IL-1beta induces an exaggerated pro- and anti-inflammatory response in peritoneal macrophages of children compared with adults. *Pediatr Surg Int* 20:238-242
- (34) Barsness KA, Bensard DD, Partrick DA, Calkins CM, Hendrickson RJ, McIntyre RC, Jr. (2004) Endotoxin induces an exaggerated interleukin-10 response in peritoneal macrophages of children compared with adults. *J Pediatr Surg* 39:912-915
- (35) Hall NJ, Jones CE, Eaton S, Stanton MP, Burge DM (2011) Is interval appendectomy justified after successful nonoperative treatment of an appendix mass in children? A systematic review. *J Pediatr Surg* 46:767-771
- (36) Chapman SJ, Shelton B, Mahmood H, Fitzgerald JE, Harrison EM, Bhangu A (2014) Discontinuation and non-publication of surgical randomised controlled trials: observational study. *BMJ* 349:g6870
- (37) Cook JA (2009) The challenges faced in the design, conduct and analysis of surgical randomised controlled trials. *Trials* 10:9
- (38) Fletcher B, Gheorghe A, Moore D, Wilson S, Damery S (2012) Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. *BMJ Open* 2:e000496

- (39) Blazeby JM (2012) Recruiting patients into randomized clinical trials in surgery. *Br J Surg* 99:307-308
- (40) Donovan J, Mills N, Smith M, et al (2002) Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. *BMJ* 325:766-770
- (41) Mills N, Donovan JL, Wade J, Hamdy FC, Neal DE, Lane JA (2011) Exploring treatment preferences facilitated recruitment to randomized controlled trials. *J Clin Epidemiol* 64:1127-1136
- (42) Kodish E, Eder M, Noll RB, et al (2004) Communication of randomization in childhood leukemia trials. *JAMA* 291:470-475
- (43) Jackson CJ, Dixon-Woods M, Eborall H, Kenyon S, Tooze-Hobson P, Tincello DG (2010) Women's views and experiences of a patient preference trial in surgery: a qualitative study of the CARPET1 trial. *Clin Trials* 7:696-704
- (44) Shilling V, Williamson PR, Hickey H, et al (2011) Communication about children's clinical trials as observed and experienced: qualitative study of parents and practitioners. *PLoS One* 6:e21604
- (45) Hickey HR, Jones AP, Lenney W, Williamson PR, Smyth RL (2010) Feasibility study to inform the design of a randomised controlled trial to eradicate *Pseudomonas aeruginosa* infection in individuals with cystic fibrosis. *Trials* 11:11
- (46) The management of otitis media with effusion (OME) in children with cleft palate: a feasibility study (MOMENT): 2012.
- (47) van't Hoff W: Recruitment to the TORPEDO-CF trial. 2012.
- (48) Harman NL, Bruce IA, Kirkham JJ, et al (2015) The Importance of Integration of Stakeholder Views in Core Outcome Set Development: Otitis Media with Effusion in Children with Cleft Palate. *PLoS One* 10:e0129514
- (49) Williamson PR, Altman DG, Blazeby JM, et al (2012) Developing core outcome sets for clinical trials: issues to consider. *Trials* 13:132
- (50) Sinha IP, Altman DG, Beresford MW, et al (2012) Standard 5: selection, measurement, and reporting of outcomes in clinical trials in children. *Pediatrics* 129 Suppl 3:S146-S152
- (51) Sinha IP, Williamson PR, Smyth RL (2009) Outcomes in clinical trials of inhaled corticosteroids for children with asthma are narrowly focussed on short term disease activity. *PLoS One* 4:e6276
- (52) Chan AW, Altman DG (2005) Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. *BMJ* 330:753
- (53) Hall NJ, Kapadia MZ, Eaton S, et al (2015) Outcome reporting in randomised controlled trials and meta-analyses of appendicitis treatments in children: a systematic review. *Trials* 16:275
- (54) Five year forward view, NHS England, (2014).
- (55) Cheong LH, Emil S (2014) Outcomes of pediatric appendicitis: an international comparison of the United States and Canada. *JAMA Surg* 149:50-55
- (56) Folaranmi SE, Jones CE, Bhangu A, Hall NJ (2014) Variation in provision and outcome of emergency appendectomy in paediatric specialist centres. *Ann R Coll Surg Engl (Suppl)* 96:9-14
- (57) Svensson JF, Patkova B, Almstrom M, et al (2015) Design of Studies for Antibiotic Treatment of Acute Appendicitis in Children: In Support of RCTs. *Ann Surg*
- (58) Chan AW, Tetzlaff JM, Altman DG, et al (2013) SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 158:200-207
- (59) St Peter SD, Sharp SW, Holcomb GW, III, Ostlie DJ (2008) An evidence-based definition for perforated appendicitis derived from a prospective randomized trial. *J Pediatr Surg* 43:2242-2245
- (60) O'Cathain A, Thomas KJ, Drabble SJ, Rudolph A, Hewison J (2013) What can qualitative research do for randomised controlled trials? A systematic mapping review. *BMJ Open* 3
- (61) O'Cathain A, Thomas KJ, Drabble SJ, Rudolph A, Goode J, Hewison J (2014) Maximising the value of combining qualitative research and randomised controlled trials in health research: the QUALitative Research in Trials (QUART) study--a mixed methods study. *Health Technol Assess* 18:1-vi
- (62) Shilling V, Williamson PR, Hickey H, Sowden E, Smyth RL, Young B (2011) Processes in recruitment to randomised controlled trials of medicines for children (RECRUIT): a qualitative study. *Health Technol Assess* 15:1-116
- (63) Crawley E, Mills N, Hollingworth W, et al (2013) Comparing specialist medical care with specialist medical care plus the Lightning Process for chronic fatigue syndrome or myalgic encephalomyelitis (CFS/ME): study protocol for a randomised controlled trial (SMILE Trial). *Trials* 14:444

- (64) Sinha IP, Smyth RL, Williamson PR (2011) Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies. *PLoS Med* 8:e1000393
- (65) Guyatt GH, Oxman AD, Kunz R, et al (2011) GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 64:395-400
- (66) Dingemann J, Ure B (2012) Imaging and the use of scores for the diagnosis of appendicitis in children. *Eur J Pediatr Surg* 22:195-200
- (67) Blakely ML, Williams R, Dassinger MS, et al (2011) Early vs interval appendectomy for children with perforated appendicitis. *Arch Surg* 146:660-665
- (68) Stevens KJ (2010) Working with children to develop dimensions for a preference-based, generic, pediatric, health-related quality-of-life measure. *Qual Health Res* 20:340-351
- (69) Stevens KJ: Assessing the performance of a new generic measure of health related quality of life for children and refining it for use in health state valuation. 9 ed. 2011. p. 157-69.
- (70) Mays N, Pope C (2000) Qualitative research in health care. Assessing quality in qualitative research. *BMJ* 320:50-52
- (71) Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 240:205-213
- (72) Fernald DH, Duclos CW (2005) Enhance your team-based qualitative research. *Ann Fam Med* 3:360-364
- (73) A proposed charter for clinical trial data monitoring committees: helping them to do their job well (2005) *Lancet* 365:711-722
- (74) Hartling L, Wittmeier KD, Caldwell PH, et al (2011) StaR Child Health: developing evidence-based guidance for the design, conduct, and reporting of pediatric trials. *Clin Pharmacol Ther* 90:727-731
- (75) Ellenberg S, Fernandes RM, Saloojee H, et al (2012) Standard 3: data monitoring committees. *Pediatrics* 129 Suppl 3:S132-S137
- (76) Drake FT, Mottey NE, Farrokhi ET, et al (2014) Time to appendectomy and risk of perforation in acute appendicitis. *JAMA Surg* 149:837-844
- (77) Hornby ST, Shahtahmassebi G, Lynch S, Ladwa N, Stell DA (2014) Delay to surgery does not influence the pathological outcome of acute appendicitis. *Scand J Surg* 103:5-11
- (78) Hall NJ, Pacilli M, Eaton S, et al (2009) Recovery after open versus laparoscopic pyloromyotomy for pyloric stenosis: a double-blind multicentre randomised controlled trial. *Lancet* 373:390-398
- (79) Ong EG, Eaton S, Wade AM, et al (2012) Randomized clinical trial of glutamine-supplemented versus standard parenteral nutrition in infants with surgical gastrointestinal disease. *Br J Surg* 99:929-938
- (80) Rees CM, Eaton S, Kiely EM, Wade AM, McHugh K, Pierro A (2008) Peritoneal drainage or laparotomy for neonatal bowel perforation? A randomized controlled trial. *Ann Surg* 248:44-51
- (81) Hall NJ, Eaton S, Peters MJ, et al (2010) Mild controlled hypothermia in preterm neonates with advanced necrotizing enterocolitis. *Pediatrics* 125:e300-e308
- (82) Mills N, Blazeby JM, Hamdy FC, et al (2014) Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences. *Trials* 15:323
- (83) Blazeby JM, Strong S, Donovan JL, et al (2014) Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer. *Br J Cancer* 111:234-240
- (84) Paramasivan S, Strong S, Wilson C, Campbell B, Blazeby JM, Donovan JL (2015) A simple technique to identify key recruitment issues in randomised controlled trials: Q-. *Trials* 16:88
- (85) Hopkins J, Howes N, Chalmers K, et al (2015) What are important outcomes of bariatric surgery? An in-depth analysis to inform the development of a core outcome set and a comparison between the views of surgeons and other health professionals (the BARIACT study). *Lancet* 385 Suppl 1:S43
- (86) Potter S, Holcombe C, Ward JA, Blazeby JM (2015) Development of a core outcome set for research and audit studies in reconstructive breast surgery. *Br J Surg* 102:1360-1371
- (87) Herdman M, Gudex C, Lloyd A, et al. (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *QualLife Res.* 20(10):1727-1736
- (88) Janssen MF, Pickard AS, Golicki D, et al. (2013) Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. *QualLife Res.* 22(7):1717-1727.
- (89) Georgiou R, Eaton S, Stanton MP, Pierro A, Hall NJ. Efficacy and Safety of Nonoperative Treatment for Acute Appendicitis: A Meta-analysis. *Pediatrics.* 2017;139(3).

- (90) Delbecq AL, Van de Ven AH, Gustafson DH. Group techniques for program planning: A guide to nominal group and Delphi processes. Illinois: Scott, Foresman and Company; 1975.
- (91) Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino M-A, et al. Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. Journal of Clinical Epidemiology. 2014;67(7):745-53.

17 APPENDICES

Appendix A: Development of a Core Outcome Set

Scope of the core outcome set

The COS is intended to be used to evaluate the overall success of treatment of acute uncomplicated appendicitis, including both operative and non-operative management. It is intended to be used in future research evaluating treatments (of all modalities) of children with acute uncomplicated appendicitis. The COS will include outcome measures identified as important within 12 months following initiation of treatment and longer term outcomes if applicable. The COS focuses specifically on treatment of acute uncomplicated appendicitis; treatment of complicated acute appendicitis including perforated appendicitis (with or without abscess) and appendix mass is outside the scope of this COS.

The key objectives of the study are:

1. To determine which outcomes have previously been reported in studies comparing treatments for acute uncomplicated appendicitis in children.
2. To prioritise treatment outcomes of children with acute uncomplicated appendicitis from key stakeholder groups' perspectives (including paediatric surgeons, general surgeons, patients [12-18 years old], and parents of children who have had acute uncomplicated appendicitis).
3. To compare and contrast paediatric acute uncomplicated appendicitis treatment outcomes prioritised by key stakeholder groups (as detailed above).
4. To achieve consensus between key stakeholder groups on a COS to evaluate overall success of treatment for acute uncomplicated appendicitis in children.

Design

COS development will entail four key stages:

1. A systematic review to identify previously reported acute uncomplicated appendicitis treatment outcomes.
2. Assembly of stakeholder panels.
3. A three-phase online Delphi process.
4. Consensus meeting.

Systematic review

The COMET Initiative recommend the use of systematic reviews in informing the first phase of the Delphi process [49]. Two recent systematic reviews will be used to inform the initial list of potential outcomes to be considered for the COS. The first review identified that there is currently no COS described for randomised controlled trials (RCTs) in children with appendicitis and aimed to identify outcomes used in studies of paediatric appendicitis [53]. The second review aimed to determine safety and efficacy of non-operative treatment for acute appendicitis, which involved systematic review and meta-analysis [89]. We will draw from these systematic reviews and conduct an updated literature search to identify outcome measures that can be used as a starting point for the development of the COS. The list of potential outcomes identified will be expanded to include additional outcomes identified from the existing literature on non-operative treatment. The research team will expand the list of outcomes by identifying additional eligible papers, using the below criteria:

1. Types of studies: any study design reporting non-operative treatment for acute uncomplicated appendicitis in children.

2. Types of participants: children (<18 years of age).
3. Exclusion criteria: studies that reported non-operative treatment as treatment of complicated appendicitis (such as perforated appendicitis, ruptured appendicitis, appendicitis with an abscess or appendix mass), studies that included a mixed population of adults and children, or studies that reported non-operative treatment as treatment of acute appendicitis only in children with malignancy.

All relevant articles will therefore be included that reported any non-operative treatment regimen for acute uncomplicated appendicitis in children with or without a comparative group of children undergoing surgical treatment. Specific time points and methods of outcome measurement will be considered as part of the scoring process in the first phase of the Delphi process. These aspects will be established via further literature review and consensus meeting discussions.

Finalising and appropriate wording of initial outcomes

The systematic review will inform an initial list of treatment outcomes. To inform and support the CONTRACT study, a Study Specific Advisory Group (SSAG) has been assembled, comprising of 15-20 young people and parents. Young people recruited are children who have had appendicitis or children from the existing Clinical Research Network (CRN) (Children) Young Persons Advisory Groups (YPAGs). Parents are parents of children who have had appendicitis. A SSAG meeting will be held to present the initial list of treatment outcomes and to inform the addition and wording of outcomes, to ensure that they can be appropriately presented to children and their parents. Three versions of the stakeholder-facing materials will be developed for all rounds of the Delphi process, for each stakeholder panel (clinicians, young people and parents), using appropriate language identified and agreed by the SSAG. Appropriate labels will be used for non-clinician stakeholder groups as defined by the SSAG.

Stakeholder panel assembly - identification and recruitment

For the COS to be meaningful and relevant to those involved in the treatment of acute appendicitis, the COS needs to reflect the views of patients who have been treated for acute appendicitis, their parents, and relevant clinicians. As these groups may have different priorities that could obstruct reaching consensus on a COS, the stakeholders will be separated into three panels, which we intend to be equally weighted: (1) patients; (2) parents; (3) paediatric surgeons and general surgeons. Potential members of each stakeholder panel will be known as 'experts'. Initially, experts known to the research team will be invited to participate and subsequently, we will develop pragmatic strategies to identify further experts. These will include use of membership lists of national organisations such as the British Association of Paediatric Surgeons and members of the Royal College of Surgeons of England known to have a particular interest in the treatment of children.

Potential experts will be invited to participate by face to face contact or mail (patients and parents) or email (surgeons). This initial contact will explain the nature of the study and why they have been identified as an expert. It will contain a plain language summary of the study aims and procedures, emphasising the importance of commitment to the panel. The wording of this initial contact will be tailored to meet the panel category. It will also contain a link to an online form to enable experts to express their interest in participation in the study and to provide further information on their experience of the treatment of acute appendicitis. We will ask experts to commit to completing three rounds of questionnaires anticipated to take approximately 10 minutes each to complete.

The process of invitation and enrolment will continue until the optimal number of experts have expressed an interest to participate (with at least ten in each panel). There is no consensus on

the optimal sample size for a Delphi study; recruitment will therefore be based on previous Delphi studies [64]. We will aim to achieve 75-100 participants in the first round of the Delphi with at least as many parents/children as surgeons. We will aim to send the first questionnaire to all experts on the same day they each confirm their desire to participate [90]. Experts will be sent a link to a customised online database hosted on a secure server, from which they can access and complete phase one questionnaire of the Delphi process. To limit attrition, appropriate procedures will be completed [64], including reminder emails.

Patients and parents – Patients and parents will be identified by clinical teams from the three sites that are participating in the CONTRACT study and also at further participant identification sites. These will be children aged 12-18 years who have been treated for acute uncomplicated appendicitis in the preceding 24 months (patients) and parents of children (any age) who have been treated for acute uncomplicated appendicitis in the preceding 24 months. These families may or may not have participated in CONTRACT. The patient and parent panels will specifically include children and parents treated initially by non-operative management as well as those treated operatively.

Paediatric surgeons – All practising consultant paediatric surgeons in the United Kingdom who treat children with acute uncomplicated appendicitis will be considered potential experts. They will be invited to participate through the mailing list of the British Association of Paediatric Surgeons and through personal contacts of the investigators.

General surgeons - Adult general surgeons in the UK who regularly treat children with acute uncomplicated appendicitis will be considered potential experts. This will include those identified as having an interest in the treatment of children.

Definition of consensus

Throughout the Delphi process and during the final consensus meeting we intend to use the following definitions: 'consensus in' will be defined as $\geq 70\%$ of participants rating the outcome 7–9, and $< 15\%$ rating it as 1–3. Outcomes will be defined as "consensus out" if $> 70\%$ participants rate it 1–3 and $< 15\%$ rate it 7–9. Outcomes not meeting these definitions will be classified as 'no consensus'. These pre-agreed criteria may be reviewed in light of the study data.

Delphi process: phase one data collection

A customised online system will be developed to conduct a three-phase Delphi process run in parallel across the stakeholder panels. Three differently worded versions of the questionnaires with background information will be available for all rounds, as appropriate for each panel (surgeons, children, parents) using language appropriate for each panel.

Experts will be presented with the initial list of outcomes, grouped by domains. As described, the initial list will comprise of outcomes identified in our recent systematic review [53], updated review of the literature and any additional outcomes identified during qualitative interviews with families, surgeons, and other clinical staff. There will also be an option for experts to add further outcomes but these outcomes will not be scored in phase one. Again, lay equivalents will be developed for use with the patient/parent panels.

Surgeon experts will be asked the key question 'How important do you consider the following outcomes to be when considering which treatment to offer children with uncomplicated acute appendicitis?' The key question to be posed to other stakeholder panel will be similar but the wording will be altered based on our SSAG input.

Each expert will be asked to provide a score for each outcome (including those they have added themselves) using the Grading of Recommendations, Assessment, Development and Evaluations

(GRADE) scale, which is recommended by the COMET initiative [12]. The scale will be presented in the format 1 to 9, with 1 to 3 labelled 'not important', 4 to 6 labelled 'important but not critical' and 7 to 9 labelled 'critical' [65]. Appropriate labels will be used for non-surgeon panels as advised by the SSAG.

Experts will be asked to complete each round of the Delphi exercise within 3 weeks and will be sent reminders via email when they have 1 week and 48 hours remaining to complete the survey. Experts who have not completed the questionnaire within 4 weeks of being requested to complete the questionnaire will be deemed not to have completed that phase.

Delphi process: phase one data analysis

The number of experts who were invited to participate in the first phase of the Delphi will be recorded, as well as the response rate each stakeholder group. Outcomes will be analysed separately for each panel and descriptive statistics will be calculated for each, including medians and interquartile ranges. All outcomes will be carried forward to the second phase.

Additional outcomes provided by experts will be reviewed by two members of the COS team to ensure they represent new outcomes and will be included and carried forward to phase two so long as they were proposed by at least two experts.

Delphi process: phase two data collection

Experts who completed phase one will be invited to participate in phase two. Experts will be individually presented with their own scores and the distribution of scores for each outcome from their stakeholder group in phase one. The scores from phase one will be presented to experts numerically and graphically. They will then be asked to rescore each outcome. Experts will also be asked to score any new outcome which was identified in phase one.

Delphi process: phase two data analysis

The number of experts who were invited to participate in the second phase of the Delphi will be recorded, as well as the response rate each stakeholder panel. Descriptive statistics will again be calculated and will be identical to phase one, however, scores for newly added outcomes will also be calculated. Bias from loss of experts between phases will be assessed by determining whether there are any differences in median phase one scores for outcomes between experts who have completed both phases and experts who completed only phase one. Any outcomes that meet the criteria of 'consensus out' based on the scores of all three stakeholder panels will be removed from the outcomes list prior to phase three. Experts will be informed that this has taken place. All other outcomes from phase two will be carried forward to phase three.

Delphi process: phase three data collection

Experts who completed phases one and two will be invited to participate in phase three. In phase three experts will be shown their own score and the distribution of scores, for each outcome, for their own stakeholder panel and separately for each other panel. This novel approach will allow surgeons to take into account the views of children and parents and vice-versa [76]. Experts will be asked to rescore all outcomes again. Finally, experts will be asked to identify the one single outcome which they believe is the most important for informing their treatment choice, and if they cannot identify a single outcome, a combination of essential outcomes.

Delphi process: phase three data analysis

The number of experts who were invited to participate in the third phase of the Delphi will be recorded, as well as the response rate for each stakeholder panel and for all experts overall.

Descriptive statistics will again be calculated and will be identical to phase two. All outcomes from phase three will be carried forward to the consensus meeting

Final consensus meeting

The aim of the consensus meeting is to ratify outcomes where consensus ('in' or 'out') has been achieved, discuss outcomes where consensus could not be achieved and to finalise the COS. All experts who have completed all 3 rounds of the Delphi exercise will be invited to attend the consensus meeting purposively with equally weighted panels and disciplines. We will aim to have a minimum of 40 experts confirm their attendance. Representatives from each stakeholder panel will be required in order for the consensus meeting to be quorate. Experts will be provided with an overview of the results of phase three of the Delphi exercise including presentation of each outcome scored, how it was scored by each stakeholder panel and its consensus status.

Following moderated discussion, each outcome will be anonymously re-scored using the same scoring system as the Delphi process. Experts will be asked to rescore outcomes based on their own scores, the results of the Delphi process and the discussions at the meeting. For those outcomes for which 'no consensus' was achieved across all stakeholder panels at the end of the Delphi exercise, and for those for which consensus was achieved in at least one but not all stakeholder groups, further discussion will take place following which attendees will be asked to score each outcome anonymously. Outcomes reaching "consensus in" (as defined in the below criteria) following re-scoring at the consensus meeting will be included in the COS. All others will be excluded. Only "consensus in" outcomes at the end of the consensus meeting will be eligible to be included in the COS.

Finalising the core outcome set

The Outcome Measures in Rheumatology (OMERACT) initiative provides a comprehensive conceptual framework and recommends a process for the development of a COS that is a useful tool for various areas of healthcare [91]. In developing the current COS, we will draw on this framework, which comprises of three core domains (Death, Life Impact and Pathophysiological Manifestations) and one strongly recommended domain (Resource Use). The framework recommends that at least one applicable measurement instrument for each core domain should be used to formulate a COS. It also recommends inclusion of 'adverse events'. Overall, we aim to achieve a manageable COS with a maximum of approximately 10 outcomes.

Sub-group analysis

For the purposes of reporting the development of the COS, a comparison of scoring of outcomes will be performed across stakeholder panels.

Data management

Experts will enter data directly into the customised database when they complete each questionnaire at each phase of the Delphi process. Anonymised data will be stored securely and will be managed as per standard operating procedures. Only selected members of the research team will have access to the data.

APPENDIX B - ADDITIONAL DATA TO BE COLLECTED

- Markers of severity of illness at randomisation including CRP, total white cell count, neutrophil count, clinical findings and need for fluid resuscitation.
- Alvarado score at randomisation (note: this will NOT be used for diagnostic purposes but as a clinical descriptor)
- Operative procedure performed – laparoscopic/open
- Operative findings - clinical description of appearance of appendix and intra-abdominal pathology
- Time of procedure
- Time between randomisation and operation in surgery group
- Precise detail of the reason for surgery in the non-operative treatment group
- Time in hospital from randomisation
- Time to resolution of symptoms from randomisation
- Abscess formation (documented by ultrasound, requiring prolonged antibiotics or drainage)
- Wound infection requiring antibiotics
- Wound dehiscence
- Total antibiotic consumption related to appendicitis (in hospital and out-patient, during 6 month follow-up)
- Compliance with out-patient antibiotic use
- Total analgesia consumption (in-hospital)
- Adverse effects of antibiotics
- Total number of intravenous cannulae required for antibiotics/intravenous fluids
- Time away from daily activities following discharge (measured using a diary card)
- Histology findings of appendicectomy specimens
- Recurrent appendicitis (histological diagnosis) requiring appendicectomy during the initial 6 month follow-up phase of this study and subsequently to a maximum of 5 years following randomisation (outside this application)
- All interventions, together with time and resource use in hospital will be identified. Resource use of community health (visits to GP, nurse and hospital out-patient) and loss of societal resources (child's days off from school, parent's days off from work) will be recorded at follow-up visits.

SUMMARY OF SIGNIFICANT CHANGES TO THE PROTOCOL

Protocol date and version	Summary of significant changes
2, 10-Apr-2017	<ul style="list-style-type: none"> • Minor clarification of SAE exceptions in section 6.2.1 • Addition of ISRCTN reference on front page
3, 04-Jul-2017	<ul style="list-style-type: none"> • Change to co-investigator at St Georges • Reference to patient video access online • Consent process oversight by SCTU • Telephone consent process for qualitative sub study • Specification of office hours for randomisation back up • Timeline for questionnaire completion • Window for AE reporting • Update to COS protocol – appendix A and references